Companion Animal Infectious Disease Diagnostics Market Size, Share and Growth Outlook, 2026

Companion Animal Infectious Disease Diagnostics Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Companion Animal Infectious Disease Diagnostics Market size is forecast to increase from $1.7 Billion in 2026 to $3.08 Billion in 2034 at a CAGR of 7.69% between 2026 and 2034.

The Companion Animal Infectious Disease Diagnostics market report provides detailed analysis and outlook of Companion Animal Infectious Disease Diagnostics segments including By Technology (Immunodiagnostics, Molecular Diagnostics, Clinical Biochemistry and Analyzers, Hematology, Urinalysis, Microbiology and Culture-based Testing), By Application (Bacteriology, Virology, Parasitology, Mycology), By Animal Type (Dogs, Cats, Equine, Other Companion Animals ), By End User (Diagnostic Laboratories, Veterinary Hospitals and Clinics, Research Institutes and Universities, Home Care Settings) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Companion Animal Infectious Disease Diagnostics Industry Overview

Advanced Diagnostic Surveillance Strengthening Infectious Disease Detection

The companion animal infectious disease diagnostics industry is evolving rapidly as veterinary laboratories expand surveillance programs, molecular testing capabilities, and pathogen monitoring initiatives. Increasing concerns regarding antimicrobial resistance, emerging infectious diseases, and zoonotic threats are driving demand for advanced diagnostic solutions across veterinary clinics, specialty hospitals, and reference laboratories. The industry is increasingly focused on delivering earlier disease identification, improved pathogen characterization, and evidence-based treatment selection through integrated laboratory diagnostics and genomic technologies.

Growing Focus on Antimicrobial Resistance Monitoring in Companion Animals

Antimicrobial resistance surveillance has become a critical area of development within companion animal diagnostics. A collaborative report published by the American Association of Veterinary Parasitologists Hookworm Task Force analyzed extensive diagnostic data generated through IDEXX and Antech diagnostic laboratories. Across more than 15,000 canine samples, researchers identified a high prevalence of a resistant allele at codon 167 of Ancylostoma caninum, reaching up to 14.4% in certain cohorts. The findings confirmed widespread multi-drug resistance against commonly used benzimidazole anthelmintics, highlighting the growing need for molecular diagnostic testing, resistance screening assays, and targeted parasite management strategies in veterinary medicine.

Biomarker-Based Testing Expanding Early Disease Detection Capabilities

The adoption of advanced biomarker diagnostics is improving the early identification of chronic and infectious diseases in companion animals. Large-scale veterinary research evaluating asymmetric dimethylarginine (SDMA) and urine protein-to-creatinine (UP/C) ratios established a framework for standardized clinicopathological testing for progressive feline illnesses. These diagnostic markers support earlier recognition of chronic organ dysfunction and associated viral complications, including Feline Immunodeficiency Virus (FIV) and Feline Leukemia Virus (FeLV), before severe systemic clinical manifestations occur. The growing utilization of biomarker-based testing is enhancing preventive care strategies and enabling more proactive disease management in feline populations.

Genomic Diagnostics and Artificial Intelligence Transforming Veterinary Laboratories

Genomic surveillance and artificial intelligence are increasingly reshaping infectious disease diagnostics workflows. Researchers operating through Vet Med Labor GmbH, part of IDEXX Laboratories, completed a comprehensive genomic analysis of multi-drug resistant Pseudomonas aeruginosa strains isolated from companion animal patients. The study identified specific resistance mechanisms and hospital-associated transmission pathways, supporting the implementation of sophisticated genotypic profiling panels within veterinary healthcare facilities. Simultaneously, companion animal reference laboratories and veterinary teaching hospitals are deploying cloud-native diagnostic AI copilot platforms that integrate with clinical pathology instruments. These systems analyze digital assay profiles, synthesize multi-indicator diagnostic information, and identify subtle serological trends associated with complex infectious diseases such as FeLV and FIV, allowing veterinary teams to initiate evidence-based interventions before overt clinical symptoms develop.

Companion Animal Infectious Disease Diagnostics Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Companion Animal Infectious Disease Diagnostics market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- IDEXX Laboratories, Inc., Zoetis Inc., Thermo Fisher Scientific Inc., bioMérieux SA, QIAGEN N.V., Neogen Corporation, Heska Corporation, Randox Laboratories Ltd., Indical Bioscience GmbH, Virbac S.A.. The Companion Animal Infectious Disease Diagnostics market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Companion Animal Infectious Disease Diagnostics industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Companion Animal Infectious Disease Diagnostics Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Companion Animal Infectious Disease Diagnostics companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Companion Animal Infectious Disease Diagnostics markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Companion Animal Infectious Disease Diagnostics Market Competitive Benchmarking and Company Analysis

Leading companies in Companion Animal Infectious Disease Diagnostics industry include- IDEXX Laboratories, Inc., Zoetis Inc., Thermo Fisher Scientific Inc., bioMérieux SA, QIAGEN N.V., Neogen Corporation, Heska Corporation, Randox Laboratories Ltd., Indical Bioscience GmbH, Virbac S.A.. The Companion Animal Infectious Disease Diagnostics market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Companion Animal Infectious Disease Diagnostics Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Companion Animal Infectious Disease Diagnostics market remains one of the strongest-performing segments in the country.
The US Companion Animal Infectious Disease Diagnostics Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Companion Animal Infectious Disease Diagnostics market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Companion Animal Infectious Disease Diagnostics industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Companion Animal Infectious Disease Diagnostics markets

Canada's strong Companion Animal Infectious Disease Diagnostics sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Companion Animal Infectious Disease Diagnostics market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Companion Animal Infectious Disease Diagnostics Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Companion Animal Infectious Disease Diagnostics market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Companion Animal Infectious Disease Diagnostics population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Companion Animal Infectious Disease Diagnostics industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Companion Animal Infectious Disease Diagnostics market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Companion Animal Infectious Disease Diagnostics sales through 2034

France Companion Animal Infectious Disease Diagnostics companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Companion Animal Infectious Disease Diagnostics Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Companion Animal Infectious Disease Diagnostics distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Companion Animal Infectious Disease Diagnostics Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Companion Animal Infectious Disease Diagnostics market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Companion Animal Infectious Disease Diagnostics industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Companion Animal Infectious Disease Diagnostics industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Companion Animal Infectious Disease Diagnostics Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Companion Animal Infectious Disease Diagnostics market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Companion Animal Infectious Disease Diagnostics market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Companion Animal Infectious Disease Diagnostics Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Companion Animal Infectious Disease Diagnostics Market Segmentation

By Technology
Immunodiagnostics
Molecular Diagnostics
Clinical Biochemistry and Analyzers
Hematology
Urinalysis
Microbiology and Culture-based Testing
By Application
Bacteriology
Virology
Parasitology
Mycology
By Animal Type
Dogs
Cats
Equine
Other Companion Animals
By End User
Diagnostic Laboratories
Veterinary Hospitals and Clinics
Research Institutes and Universities
Home Care Settings

Top Companies in Companion Animal Infectious Disease Diagnostics Industry

IDEXX Laboratories, Inc.
Zoetis Inc.
Thermo Fisher Scientific Inc.
bioMérieux SA
QIAGEN N.V.
Neogen Corporation
Heska Corporation
Randox Laboratories Ltd.
Indical Bioscience GmbH
Virbac S.A.

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Rise of Functional and Clinical-Grade Skincare

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025